Karling Pontus, Norrback Karl-Fredrik, Adolfsson Rolf, Danielsson Ake
Department of Medicine/Gastroenterology, Umeå University Hospital, Umeå, Sweden.
Scand J Gastroenterol. 2007 Nov;42(11):1294-301. doi: 10.1080/00365520701395945.
The brain-gut axis has been proposed to influence symptoms in irritable bowel syndrome (IBS). In animal studies corticotropin-releasing hormone (CRH) challenge has been associated with decreased upper gastrointestinal motility and increased colonic motility. The purpose of this study was to investigate the association between gastrointestinal symptoms and the effect of CRH on the hypothalamic-pituitary-adrenal (HPA) axis using a weight-adjusted low-dose dexamethasone test in a group of healthy individuals (n = 157).
Pre- and post-dexamethasone morning serum cortisol was analysed. All participants completed questionnaires regarding symptoms of IBS (GSRS-IBS (Gastrointestinal Symptom Rating Scale-IBS) and symptoms of anxiety and depression (HADS (Hospital Anxiety and Depression Scale)). After exclusions, 124 subjects were available for analysis (F/M: 60/64, mean age 55.8 years, SD 15.4, range 21-80 years).
A positive correlation was found between the GSRS-IBS score and HADS score (rs =0.36; p <0.001). There was no linear correlation between either pre- (rs = 0.145; p = 0.11) or post-dexamethasone cortisol levels (rs =0.087; p =0.337) and GSRS-IBS scores. By subgrouping the subjects at the lower and higher 25th percentiles of their post-dexamethasone morning cortisol levels, we found a trend towards a higher GSRS-IBS score (median 7.0 versus 5.0; p =0.069) (multivariate adjusted OR 2.6; CI 0.80-8.3) and a significantly higher diarrhoea score (median 2 versus 0; p = 0.021) (multivariate adjusted OR 5.7; CI 1.5-22), and a higher early satiety score (p=0.008) (multivariate adjusted OR 6.7; CI: 1.9-23) in the subjects with high post-dexamethasone cortisol levels (low HPA suppression) compared with the subjects with intermediate post-dexamethasone cortisol levels. Furthermore, individuals with low post-dexamethasone cortisol levels (high HPA suppression) showed a significant, higher score for diarrhoea (median 2.0 versus 0; p =0.010) (multivariate adjusted OR 6.1; CI 1.8-20) and early satiety (p=0.076) (multivariate adjusted OR 3.2; CI 1.0-10) compared with those with intermediate cortisol levels.
A trend toward a non-linear relationship between IBS-like symptoms and post-dexamethasone cortisol levels was observed in healthy individuals, with significantly more symptoms of diarrhoea and early satiety in individuals with high or low post-dexamethasone cortisol levels in comparison with those with intermediate post-dexamethasone cortisol levels.
脑-肠轴被认为会影响肠易激综合征(IBS)的症状。在动物研究中,促肾上腺皮质激素释放激素(CRH)激发试验与上消化道动力下降及结肠动力增加有关。本研究的目的是在一组健康个体(n = 157)中,使用体重调整后的低剂量地塞米松试验,研究胃肠道症状与CRH对下丘脑-垂体-肾上腺(HPA)轴影响之间的关联。
分析地塞米松给药前后早晨的血清皮质醇水平。所有参与者均完成了关于IBS症状(GSRS-IBS(胃肠道症状评分量表-IBS))以及焦虑和抑郁症状(HADS(医院焦虑抑郁量表))的问卷调查。排除部分个体后,124名受试者可供分析(男/女:60/64,平均年龄55.8岁,标准差15.4,年龄范围21 - 80岁)。
GSRS-IBS评分与HADS评分之间存在正相关(rs = 0.36;p < 0.001)。地塞米松给药前(rs = 0.145;p = 0.11)或给药后(rs = 0.087;p = 0.337)的皮质醇水平与GSRS-IBS评分之间均无线性相关性。通过将受试者按照地塞米松给药后早晨皮质醇水平的第25百分位数分为较低和较高两组,我们发现,与地塞米松给药后皮质醇水平处于中等的受试者相比,地塞米松给药后皮质醇水平较高(HPA抑制较低)的受试者中,GSRS-IBS评分有升高趋势(中位数7.0对5.0;p = 0.069)(多变量调整OR 2.6;CI 0.80 - 8.3),腹泻评分显著更高(中位数2对0;p = 0.021)(多变量调整OR 5.7;CI 1.5 - 22),早饱评分更高(p = 0.008)(多变量调整OR 6.7;CI:1.9 - 23)。此外,与皮质醇水平处于中等的个体相比,地塞米松给药后皮质醇水平较低(HPA抑制较高)的个体腹泻评分显著更高(中位数2.0对0;p = 0.010)(多变量调整OR 6.1;CI 1.8 - 20),早饱评分也更高(p = 0.076)(多变量调整OR 3.2;CI 1.0 - 10)。
在健康个体中观察到IBS样症状与地塞米松给药后皮质醇水平之间存在非线性关系的趋势,与地塞米松给药后皮质醇水平处于中等的个体相比,地塞米松给药后皮质醇水平高或低的个体腹泻和早饱症状明显更多。